FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115414377> ?p ?o ?g. }

• W2115414377 endingPage "458" @default.
• W2115414377 startingPage "452" @default.
• W2115414377 abstract "Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48-week peginterferon (PEG-IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72-week PEG-IFN/RBV and the predictive factors to such therapy in a case–control study matched for sex, age, and periods from the start of treatment to initial point of HCV RNA-negative. We compared the treatment efficacy of 72-week regimen in 65 patients with that of 48-week in 130 patients, who were infected with HCV genotype 1b and treated with PEG-IFN/RBV. They consisted mainly of late virological responders (LVR) (HCV RNA-positive at 12 weeks and negative at 24 weeks after start of treatment). Sustained virological response (SVR) was achieved by 61.5% and 32.3% of patients of the 72- and 48-week groups, respectively, while non-virological response was noted in 9.2% and 29.2% of the respective groups. Multivariate analysis identified substitution of aa 70 and 91 (Arg70 and/or Leu91) and duration of treatment (72-week) as independent parameters that significantly influenced SVR. For Arg70 and/or Leu91 of core region, SVR rate was significantly higher in 72- (68.0%) than 48-week group (37.8%). For wild-type of ISDR, SVR rate was significantly higher in 72- (61.2%) than in 48-week group (29.3%). We conclude that 72-week PEG-IFN/RBV improves SVR rate for LVR, especially those with Arg70 and/or Leu91 of core region or wild-type of ISDR. Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV. J. Med. Virol. 81:452–458, 2009. © 2009 Wiley-Liss, Inc." @default.
• W2115414377 created "2016-06-24" @default.
• W2115414377 creator A5002269464 @default.
• W2115414377 creator A5010056452 @default.
• W2115414377 creator A5014470642 @default.
• W2115414377 creator A5015577892 @default.
• W2115414377 creator A5022738328 @default.
• W2115414377 creator A5024325916 @default.
• W2115414377 creator A5026182073 @default.
• W2115414377 creator A5031710130 @default.
• W2115414377 creator A5044932403 @default.
• W2115414377 creator A5057057637 @default.
• W2115414377 creator A5066429603 @default.
• W2115414377 creator A5071497400 @default.
• W2115414377 creator A5084522512 @default.
• W2115414377 creator A5089243471 @default.
• W2115414377 date "2009-03-01" @default.
• W2115414377 modified "2023-10-15" @default.
• W2115414377 title "A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response" @default.
• W2115414377 cites W1602744086 @default.
• W2115414377 cites W1971792395 @default.
• W2115414377 cites W1979065789 @default.
• W2115414377 cites W1986669484 @default.
• W2115414377 cites W1987749699 @default.
• W2115414377 cites W2002605069 @default.
• W2115414377 cites W2015571005 @default.
• W2115414377 cites W2016205218 @default.
• W2115414377 cites W2018198271 @default.
• W2115414377 cites W2018446644 @default.
• W2115414377 cites W2022073038 @default.
• W2115414377 cites W2024049300 @default.
• W2115414377 cites W2027252289 @default.
• W2115414377 cites W2027545702 @default.
• W2115414377 cites W2056932404 @default.
• W2115414377 cites W2071221293 @default.
• W2115414377 cites W2071586067 @default.
• W2115414377 cites W2075293916 @default.
• W2115414377 cites W2075660007 @default.
• W2115414377 cites W2088089910 @default.
• W2115414377 cites W2088974319 @default.
• W2115414377 cites W2090153322 @default.
• W2115414377 cites W2102518994 @default.
• W2115414377 cites W2126365434 @default.
• W2115414377 cites W2127685726 @default.
• W2115414377 cites W2130283340 @default.
• W2115414377 cites W2149008840 @default.
• W2115414377 cites W2159954692 @default.
• W2115414377 cites W2165880492 @default.
• W2115414377 cites W2327525734 @default.
• W2115414377 cites W2334197314 @default.
• W2115414377 cites W2335845212 @default.
• W2115414377 cites W2336799715 @default.
• W2115414377 doi "https://doi.org/10.1002/jmv.21400" @default.
• W2115414377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19152407" @default.
• W2115414377 hasPublicationYear "2009" @default.
• W2115414377 type Work @default.
• W2115414377 sameAs 2115414377 @default.
• W2115414377 citedByCount "64" @default.
• W2115414377 countsByYear W21154143772012 @default.
• W2115414377 countsByYear W21154143772013 @default.
• W2115414377 countsByYear W21154143772014 @default.
• W2115414377 countsByYear W21154143772015 @default.
• W2115414377 countsByYear W21154143772016 @default.
• W2115414377 countsByYear W21154143772017 @default.
• W2115414377 crossrefType "journal-article" @default.
• W2115414377 hasAuthorship W2115414377A5002269464 @default.
• W2115414377 hasAuthorship W2115414377A5010056452 @default.
• W2115414377 hasAuthorship W2115414377A5014470642 @default.
• W2115414377 hasAuthorship W2115414377A5015577892 @default.
• W2115414377 hasAuthorship W2115414377A5022738328 @default.
• W2115414377 hasAuthorship W2115414377A5024325916 @default.
• W2115414377 hasAuthorship W2115414377A5026182073 @default.
• W2115414377 hasAuthorship W2115414377A5031710130 @default.
• W2115414377 hasAuthorship W2115414377A5044932403 @default.
• W2115414377 hasAuthorship W2115414377A5057057637 @default.
• W2115414377 hasAuthorship W2115414377A5066429603 @default.
• W2115414377 hasAuthorship W2115414377A5071497400 @default.
• W2115414377 hasAuthorship W2115414377A5084522512 @default.
• W2115414377 hasAuthorship W2115414377A5089243471 @default.
• W2115414377 hasConcept C104317684 @default.
• W2115414377 hasConcept C126322002 @default.
• W2115414377 hasConcept C135763542 @default.
• W2115414377 hasConcept C142462285 @default.
• W2115414377 hasConcept C159047783 @default.
• W2115414377 hasConcept C2522874641 @default.
• W2115414377 hasConcept C2776408679 @default.
• W2115414377 hasConcept C2776999253 @default.
• W2115414377 hasConcept C2780040827 @default.
• W2115414377 hasConcept C2781413609 @default.
• W2115414377 hasConcept C55493867 @default.
• W2115414377 hasConcept C71924100 @default.
• W2115414377 hasConcept C86803240 @default.
• W2115414377 hasConcept C90924648 @default.
• W2115414377 hasConceptScore W2115414377C104317684 @default.
• W2115414377 hasConceptScore W2115414377C126322002 @default.
• W2115414377 hasConceptScore W2115414377C135763542 @default.
• W2115414377 hasConceptScore W2115414377C142462285 @default.
• W2115414377 hasConceptScore W2115414377C159047783 @default.

• next